ArticleMedical oncology (Northwood, London, England)2014
Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Overexpressing lipid raft protein STOML2 modulates the tumor microenvironment via NF-κB signaling in colorectal cancer.Cellular and molecular life sciences : CMLS · 2024Article
- Expression of STOML2 promotes proliferation and glycolysis of multiple myeloma cells via upregulating PAI-1.Journal of orthopaedic surgery and research · 2021Article
- Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer.Oncology reports · 2021Article
- Stomatin-like protein 2 inhibits cisplatin-induced apoptosis through MEK/ERK signaling and the mitochondrial apoptosis pathway in cervical cancer cells.Cancer science · 2018Article
- Reduced Expression of FADS1 Predicts Worse Prognosis in Non-Small-Cell Lung Cancer.Journal of Cancer · 2016Article
- Increased APOBEC3B Predicts Worse Outcomes in Lung Cancer: A Comprehensive Retrospective Study.Journal of Cancer · 2016Article
- Recurring DNA copy number gain at chromosome 9p13 plays a role in the activation of multiple candidate oncogenes in progressing oral premalignant lesions.Cancer medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stomatin-like protein 2 (STOML2), a member of the stomatin, has been reported to be upregulated in several human cancers. However, its role and clinical significance in gastric adenocarcinoma remains unclear to date. The purpose of this retrospective study was to explore whether there was a correlation between the expression of STOML2 by immunohistochemistry and the clinical outcome of a large group of patients with gastric adenocarcinoma. In this retrospective study, we performed immunohistochemistry to evaluation of STOML2 expression in a large panel of gastric adenocarcinoma samples. The receiver operating characteristic method was used to define the STOML2 immunoreactivity score cutoff value. The clinical/prognostic significance of STOML2 expression was analyzed statistically. Kaplan-Meier analysis was used to compare the postoperative survival between groups. STOML2 was overexpressed in gastric cancer compared with paracancerous normal mucosa. Increased STOML2 expression was associated with higher histologic grade (P = 0.047), T category (P < 0.001), and N category (P = 0.01). Patients with high expression of STOML2 demonstrated shortened overall survival compared with those with low expression of STOML2 (median of 38.9 vs. 64.0 months, P < 0.001). Furthermore, STOML2 expression could stratify patients survival in stage N0 (P < 0.001). Multivariate analysis showed that the level of STOML2 expression was an independent prognostic factor in gastric adenocarcinoma (RR = 1.920, P = 0.001). Increased expression of STOML2 suggests unfavorable prognosis for gastric adenocarcinoma patients. Further studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.